The PrIMAVeRa project recently convened its third meeting with the Scientific Advisory Committee (SAC) to review outcomes and progress during the second project year and to receive guidance for future plans.
June 2024
The SAC of PrIMAVeRa comprises international experts in epidemiology, vaccinology, public health, and antimicrobial resistance (AMR) research, representing the University of Edinburgh, Israel Institute of Technology Rambam Health Care Campus, the Swiss Canton of Vaud, and the World Health Organisation. The consortium appreciates the valuable input from all SAC members and extends sincere thanks for their time and dedication.
Divided into two rounds on 7th of June and 21st of June, Consortium partners presented year two progress toward the project’s goal of developing a decision-making tool integrating an epidemiological repository with mathematical models to prioritise vaccines and monoclonal antibodies (mAbs) for combating AMR. Development is underway on compartmental and individual-based models to predict the impacts of vaccines and mAbs against 4 different pathogen-infection combinations, the search for individual-level data, as well as the storage and dissemination of that data is ongoing, and strategies for evaluation and testing of the models for real-world applicability are now being conceptualised.
Following updates, project partners and SAC members engaged in a productive Q&A session, exchanging valuable insights and suggestions. PrIMAVeRa partners look forward to the continuation of their work, and eagerly anticipate the next interaction with this valuable advisory group.
This work has received support from the IMI2/EU/EFPIA Joint Undertaking Inno4Vac grant n° 101034420 [PrIMAVeRa]. This reflects the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use made of the information contained therein.
Comments